Sign In
Buy MRNA
$59.81
+0.640 (+1.08%)
At Close: Aug 10, 2026
MRNA Stock Jumps on CDC's Revised RSV Vaccine Recommendations
10:11am, Thursday, 03'rd Jul 2025
Moderna rises as CDC expands RSV vaccine guidance to include high-risk adults aged 50-59, boosting mResvia's reach.
RFK Jr. Just Did The Unexpected. He Helped Moderna.
01:18pm, Wednesday, 02'nd Jul 2025
Moderna stock popped Wednesday after the CDC recommended the company's RSV vaccine for at-risk adults in their 50s.
Moderna Stock Gains on Encouraging Flu Vaccine Data
10:20am, Tuesday, 01'st Jul 2025
MRNA's mRNA-1010 flu vaccine outperforms GSK's shot by 26.6% in a large phase III trial of adults 50 and older.
Got $200? 2 Biotech Stocks to Buy and Hold Forever
07:15am, Tuesday, 01'st Jul 2025
Some potential investors hesitate to get started on building an investment portfolio because they think they need thousands of dollars to grow wealth. But I've got good news for them and for you: You
Top Stock Movers Now: Hewlett Packard Enterprise, Moderna, Tesla, and More
12:00pm, Monday, 30'th Jun 2025
U.S. equities gained at midday, with the S&P 500 and Nasdaq adding to their all-time highs, on optimism about more U.S. trade deals. The Dow Jones Industrial Average was up as well.
Moderna Shares Jump With Positive Test Results for MRNA Flu Vaccine
10:38am, Monday, 30'th Jun 2025
The biotechnology company's messenger RNA flu vaccine candidate showed positive results in a late-stage trial.
Moderna's influenza vaccine superior to licensed shot in study
07:22am, Monday, 30'th Jun 2025
Moderna said its experimental influenza vaccine showed superior efficacy compared with a licensed standard-dose seasonal flu shot in adults aged 50 years and older in a late-stage study.
Moderna's flu vaccine shows positive late-stage trial results, paving way for combination Covid shot
07:00am, Monday, 30'th Jun 2025
Moderna said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot for the virus in a late-stage trial. The positive data pave the way for Moderna
Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine
07:00am, Monday, 30'th Jun 2025
mRNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older CAMBRI
Moderna (MRNA) Outperforms Broader Market: What You Need to Know
06:51pm, Thursday, 26'th Jun 2025
In the closing of the recent trading day, Moderna (MRNA) stood at $27.54, denoting a +2.53% move from the preceding trading day.
Moderna (MRNA) Advances While Market Declines: Some Information for Investors
06:51pm, Friday, 20'th Jun 2025
In the most recent trading session, Moderna (MRNA) closed at $25.90, indicating a +1.97% shift from the previous trading day.
Moderna, Inc. (MRNA) Presents at Barclays Speaking the Science Call Series Transcript
04:44pm, Monday, 16'th Jun 2025
Moderna, Inc. (NASDAQ:MRNA ) Barclays Speaking the Science Call Series Call June 16, 2025 10:00 AM ET Company Participants Lavina Talukdar - Senior VP & Head of Investor Relations Rose Loughlin - Exec
Here's Why Moderna (MRNA) Fell More Than Broader Market
06:51pm, Friday, 13'th Jun 2025
Moderna (MRNA) closed the most recent trading day at $26.68, moving 2.45% from the previous trading session.
Moderna falls on fears new CDC vaccine advisory panel could cloud RSV shot prospects
08:42am, Friday, 13'th Jun 2025
Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the company's respiratory syncytial virus vaccine in a broader age group.
US FDA approves expanded use of Moderna's RSV vaccine for at-risk adults
07:35pm, Thursday, 12'th Jun 2025
The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a lower group of high-risk adults aged 18 to 59 years.
